Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

GlaxoSmithKline Pharmaceuticals reports a 12% increase in net profit to Rs 279 crore for the June quarter despite a slight ...

Pharma giant Glaxosmithkline, which has major operations in Upper Providence and West Point, is partnering with China-based ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £21.70. The company’s shares closed today at p1,373.00. Take advantage of ...

July 14, 2010 -- In the face of mounting evidence that GlaxoSmithKline withheld important safety data on their controversial drug Avandia, some doctors are abandoning use of this diabetes treatment.

GlaxoSmithKline wants to better understand biology so it can discover more medicines, like every other drugmaker. It also wants to quit wasting money on drug candidates that look promising in the ...

According to the GlaxoSmithKline's most recent balance sheet as reported on March 6, 2020, total debt is at $40.48 billion, with $31.30 billion in long-term debt and $9.18 billion in current debt ...

Sanofi and GlaxoSmithKline are trailing other drugmakers in the race to distribute COVID-19 inoculations despite being two of the world’s biggest vaccine businesses.

GlaxoSmithKline PLC has abandoned a plan to sell some of the North American and European brands in its so-called established products portfolio after failing to find a buyer at the right price.

GlaxoSmithKline today participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting convened to discuss recent findings of porcine circovirus (PCV) in rotavirus vaccines.